#1 Clinical Trials Search in Europe

DESMOPRESSIN ACETATE

Desmopressin acetate, also known as DDAVP, is a synthetic analog of the natural antidiuretic hormone vasopressin. This medication has been studied in various clinical trials for multiple conditions, including nocturnal enuresis (bedwetting), nocturia (frequent nighttime urination), bleeding disorders, and certain types of hemophilia. Research has focused on understanding how desmopressin works in different patient populations, its optimal dosing, safety profile, and comparative effectiveness against other treatments. This article explores the current clinical research on desmopressin acetate and what it means for patients with these conditions.

Table of Contents

What is Desmopressin Acetate?

Desmopressin acetate (also known as DDAVP, Minirin, Nocturin, or Minirin Melt) is a synthetic version of vasopressin, a hormone naturally produced by the pituitary gland. Desmopressin is a medication used to treat several conditions related to water balance in the body and certain bleeding disorders. It’s a modified form of the natural hormone that has enhanced antidiuretic (water-retaining) effects while reducing other unwanted effects of natural vasopressin [1].

How Desmopressin Works

Desmopressin works primarily by binding to vasopressin type 2 receptors (V2R) in the kidneys. When it attaches to these receptors, it causes the kidneys to reabsorb more water, reducing urine production. This helps the body retain water and produces more concentrated urine. In addition to its effects on the kidneys, desmopressin also causes endothelial cells to release von Willebrand factor (VWF) and factor VIII into the bloodstream, which are important proteins for blood clotting [2].

Medical Uses

Nocturnal Enuresis (Bedwetting)

One of the most common uses of desmopressin is for treating nocturnal enuresis (bedwetting) in children. This condition affects approximately 18% of younger school-age children in Egypt and is a worldwide health problem. For children with primary monosymptomatic nocturnal enuresis (bedwetting without daytime urinary symptoms), desmopressin helps by reducing the amount of urine produced during sleep [3].

Desmopressin has shown effectiveness in reducing the frequency of bedwetting episodes in children. Studies have demonstrated that it can significantly decrease the number of wet nights compared to placebo. The medication works quickly, often showing results within days of starting treatment [4].

In one study comparing desmopressin to oxybutynin (another medication used for urinary issues), both medications were evaluated for their efficacy and safety in treating nocturnal enuresis in children. The study measured outcomes such as frequency of nocturnal enuresis, urinary incontinency, and various side effects [4].

Desmopressin is also being studied for bedwetting in children with special conditions, such as sickle cell disease, where nighttime bedwetting affects up to 30% of children [5].

Nocturia in Adults

Desmopressin is used to treat nocturia (excessive nighttime urination) in adults. Nocturia can be caused by various factors, including nocturnal polyuria (excessive urine production at night), reduced bladder capacity, or a combination of both [6].

For adults with nocturia due to nocturnal polyuria, desmopressin helps by decreasing nighttime urine production. This can lead to fewer nighttime voids, longer periods of undisturbed sleep, and improved quality of life [7].

A randomized, double-blind, placebo-controlled study investigated the efficacy and safety of several doses of the melt formulation of desmopressin in adult patients with nocturia. The study found that desmopressin reduced the number of nocturnal voids and increased the initial period of undisturbed sleep compared to placebo [1].

Desmopressin is also being studied for treating nocturia in patients with benign prostatic hyperplasia (BPH). In a clinical trial, desmopressin was added to tamsulosin (a medication commonly used for BPH) to evaluate its effects on nocturia and nocturnal polyuria in these patients [8].

Bleeding Disorders

Desmopressin is used to treat or prevent bleeding in certain bleeding disorders. It’s particularly useful for:

  • Mild to moderate hemophilia A: Desmopressin increases factor VIII levels in the blood, which helps with blood clotting [9].
  • Von Willebrand disease: Desmopressin increases von Willebrand factor levels, which are important for platelet function and blood clotting [10].
  • Platelet function disorders: Desmopressin can improve platelet function in some cases [6].

In patients with bleeding disorders, desmopressin is often given before surgical procedures to reduce the risk of excessive bleeding. The response to desmopressin varies between individuals, so a therapeutic test is usually performed before using it for treatment [9].

A study investigating genetic factors influencing the factor VIII response to desmopressin in carriers of hemophilia A found that the medication increases the level of endogenous factor VIII, thus avoiding the need for potentially immunogenic exogenous factor VIII. It’s also cheaper than factor VIII concentrates and more widely available in pharmacies in hospitals with emergency rooms and surgical facilities [2].

Other Medical Uses

Desmopressin has several other medical uses, including:

  • Diabetes insipidus: A condition where the body can’t regulate fluid balance, resulting in excessive thirst and urination [1].
  • Treating bleeding in patients on antiplatelet therapy: Desmopressin may help counteract the effects of medications like aspirin that affect platelet function [11].
  • Diagnostic testing: Desmopressin is used in tests to evaluate kidney function and the body’s ability to concentrate urine [12].

Researchers are also exploring new potential uses for desmopressin. For example, a study is investigating whether desmopressin administered before surgery in breast cancer patients could help reduce the spread of cancer cells that might be released during tumor manipulation [13].

Dosage Forms and Administration

Desmopressin is available in several forms:

  • Tablets: Oral tablets taken by mouth, typically in doses ranging from 0.1 mg to 0.4 mg [14].
  • Oral lyophilisate (melt): A tablet that dissolves under the tongue without water. These are available in various strengths, including 25 μg, 50 μg, 60 μg, 120 μg, and 240 μg [15].
  • Nasal spray: Sprayed into the nostrils [1].
  • Injectable solution: Administered intravenously or subcutaneously by a healthcare provider [16].

The dosage and form of desmopressin depend on the condition being treated, the patient’s age, weight, and response to the medication. For example, for children with nocturnal enuresis, the typical oral lyophilisate dose might be 120 μg at bedtime, while for adults with nocturia, the dose might range from 25 μg to 100 μg [15].

A bioequivalence study compared the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions. The study evaluated maximum observed concentration (Cmax) and area under the concentration-time curve (AUC) to determine if the formulations were equivalent [14].

Side Effects and Safety Considerations

Desmopressin is generally well-tolerated, but it can cause side effects, including:

  • Headache
  • Nausea
  • Mild abdominal cramps
  • Facial flushing
  • Nasal congestion (with nasal spray)

The most serious potential side effect is hyponatremia (low sodium levels in the blood) due to water retention. This is more likely to occur if excessive fluids are consumed while taking desmopressin. Symptoms of hyponatremia can include headache, nausea, vomiting, confusion, seizures, and in severe cases, coma [17].

To reduce the risk of hyponatremia, patients are advised to:

  • Limit fluid intake from 1 hour before until 8 hours after taking desmopressin
  • Have serum sodium levels monitored, especially when starting treatment
  • Be aware of symptoms of hyponatremia and seek medical attention if they occur

Desmopressin should be used with caution in certain groups, including elderly patients, young children, and those with conditions that might increase the risk of water retention or hyponatremia [15].

In a long-term safety and tolerability study of desmopressin orally disintegrating tablets for nocturia, researchers monitored adverse events, changes in laboratory values and vital signs, and the incidence and severity of hyponatremia during treatment [15].

Effectiveness and Treatment Response

The effectiveness of desmopressin varies depending on the condition being treated and individual factors. For nocturnal enuresis in children, studies have shown that about 70% of patients experience a significant reduction in wet nights while using the medication [18].

For nocturia in adults, clinical trials have demonstrated that desmopressin can reduce the number of nighttime voids by about 40-50% and increase the initial period of undisturbed sleep by 1-2 hours [1].

The response to desmopressin in bleeding disorders is more variable and depends on the specific disorder and the individual’s baseline levels of clotting factors. In mild to moderate hemophilia A, desmopressin typically increases factor VIII levels by 2-4 times the baseline level [2].

Factors that may influence the response to desmopressin include:

  • Age
  • Gender
  • Weight
  • Specific genetic mutations (in bleeding disorders)
  • Baseline levels of the affected hormones or factors
  • Concurrent medications

A study on the pharmacokinetics and pharmacodynamics of desmopressin in children found that the dose response may vary based on age and weight. This highlights the importance of individualizing treatment based on patient characteristics [12].

Special Populations

Children

Desmopressin is commonly used in children for treating nocturnal enuresis. The dosage is typically adjusted based on the child’s weight and age. For children younger than 5 years, desmopressin is generally not recommended for bedwetting as spontaneous resolution is common at this age [19].

A study comparing posterior tibial nerve stimulation to desmopressin in children with primary monosymptomatic nocturnal enuresis found that both treatments were viable options, with desmopressin being particularly useful when there are no contraindications or concerns about side effects [3].

Elderly Patients

Elderly patients may be more susceptible to hyponatremia when taking desmopressin. Lower starting doses and careful monitoring of fluid intake and serum sodium levels are recommended for this population [20].

Patients with Renal Impairment

Desmopressin should be used with caution in patients with renal (kidney) impairment, as they may have altered response to the medication and increased risk of side effects [17].

Patients with Bleeding Disorders

For patients with bleeding disorders, the response to desmopressin depends on the specific disorder and genetic factors. A therapeutic test is usually performed to assess the individual’s response before using desmopressin for treatment [9].

A study on genetic factors influencing the factor VIII response to desmopressin in carriers of hemophilia A found that certain genetic variations may affect how well patients respond to the medication [2].

Ongoing Research

Research on desmopressin continues to explore new uses and optimize treatment protocols for existing indications. Some areas of current research include:

  • Combination therapies: Studies are investigating the combination of desmopressin with other medications for enhanced efficacy. For example, a trial is looking at adding desmopressin to tamsulosin for treating nocturnal polyuria in patients with benign prostatic obstruction [8].
  • Genetic factors affecting response: Researchers are studying how genetic variations influence the response to desmopressin, particularly in bleeding disorders like hemophilia A [2].
  • Cancer applications: Studies are examining whether desmopressin might help reduce cancer spread during surgery by affecting the survival of tumor cells released into circulation [13].
  • Optimizing dosing regimens: Research is focused on finding the most effective dosing regimens while minimizing side effects, particularly in special populations like children and the elderly [12].
  • Novel formulations: Development of new formulations, such as orally disintegrating tablets (melts), aim to improve convenience and absorption [1].

A pharmacokinetic/dynamic study is investigating the characteristics of desmopressin melt in nocturia patients compared to healthy volunteers and children. The study aims to understand if differences in response are related to pathophysiological factors involved in nocturia, if there are age/gender/size differences, and if it’s possible to identify patients who are likely to develop hyponatremia [21].

Aspect Details
Common Uses • Treatment of nocturnal enuresis (bedwetting) in children
• Management of nocturia in adults
• Treatment of nocturnal polyuria
• Management of bleeding disorders (von Willebrand disease, hemophilia A)
• Improvement of platelet function
Formulations • Oral tablets (0.1-0.2 mg)
• Oral lyophilisate/melt (25-240 μg)
• Injectable solution (intravenous administration)
• Nasal spray (less commonly used now)
Nocturnal Enuresis in Children • Significantly reduces bedwetting episodes
• Comparable efficacy to treatments like oxybutynin
• Often dosed at 120-240 μg for melt formulation
• Relapse may occur after discontinuation
• Alternative to alarm therapy
Nocturia in Adults • Reduces nighttime voids by decreasing urine production
• Improves quality of sleep and first undisturbed sleep period
• Effective for nocturia associated with BPH
• Dose typically lower for adults (25-50 μg for men, 25 μg for women)
Bleeding Disorders • Increases von Willebrand factor and Factor VIII levels
• Used in mild to moderate hemophilia A
• Beneficial for perioperative management
• Can improve platelet function in certain conditions
• Effective in bleeding from platelet dysfunction
Side Effects • Hyponatremia (low sodium) – most serious concern
• Headache
• Nausea
• Abdominal pain
• Fluid retention
• Higher risk in elderly patients
Clinical Trial Findings • Dose-dependent response in both children and adults
• Gender differences in optimal dosing
• Age-related differences in response and side effect profile
• Individualized dosing may improve safety
• Long-term safety established in appropriate patients

FAQ

  • What conditions is desmopressin acetate commonly used to treat? Desmopressin acetate is primarily used to treat several conditions including nocturnal enuresis (bedwetting) in children, nocturia (excessive nighttime urination) in adults, nocturnal polyuria (overproduction of urine at night), certain bleeding disorders including mild hemophilia A and von Willebrand disease, and to improve platelet function in patients with platelet dysfunction. It works by reducing urine production through increased water reabsorption in the kidneys and by increasing certain blood clotting factors.
  • How effective is desmopressin for treating bedwetting in children? Clinical trials show that desmopressin is effective for many children with primary monosymptomatic nocturnal enuresis (bedwetting without other urinary symptoms). Multiple studies have demonstrated a significant reduction in bedwetting episodes when using desmopressin compared to before treatment. However, there is often a relapse rate after discontinuation of the medication. Different formulations, including tablets and oral lyophilisate (melt) formulations, have been studied with similar effectiveness. Some trials also compare desmopressin to other treatments like oxybutynin or behavioral therapies, showing that treatment selection may need to be tailored to the individual child.
  • What are the side effects of desmopressin acetate? The most serious potential side effect of desmopressin is hyponatremia (low sodium levels in the blood) due to water retention. This is more common in elderly patients and with higher doses. Clinical trials carefully monitor sodium levels as a safety precaution. Other possible side effects include headache, nausea, mild abdominal pain, facial flushing, and nasal congestion (with nasal spray formulations). Less common side effects may include dizziness, increased blood pressure, and allergic reactions. Most side effects are mild and temporary, though proper hydration management is important while taking this medication to prevent hyponatremia.
  • How does desmopressin acetate work for bleeding disorders? For bleeding disorders, desmopressin works by stimulating the release of von Willebrand factor and Factor VIII from blood vessel walls into the bloodstream. This helps improve blood clotting in patients with certain types of hemophilia A (particularly mild or moderate forms) and von Willebrand disease. Clinical trials have examined the optimal timing and dosing for surgical procedures and to control bleeding episodes. The medication can be particularly beneficial because it allows patients to use their own body's clotting factors rather than requiring external factor replacement therapy, which may carry additional risks.
  • What are the different formulations of desmopressin acetate and how do they differ? Desmopressin acetate comes in several formulations: oral tablets, oral lyophilisate (melt) tablets that dissolve under the tongue without water, nasal spray, and injectable solutions for intravenous or subcutaneous administration. The melt formulation typically has better bioavailability than standard tablets because it bypasses first-pass metabolism in the liver. Injectable forms are often used for immediate effect in bleeding disorders or before surgery. Nasal sprays were historically common but have been largely replaced by oral formulations in many countries. Each formulation has different dosing requirements, with tablets typically available in 0.1-0.2 mg doses and melts in various microgram doses (25-240 μg).

Ongoing Clinical Trials on DESMOPRESSIN ACETATE

  • Study Comparing Desmopressin and Desmopressin Acetate in Children with Bedwetting (Nocturnal Enuresis)

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of Desmopressin for Prevention of Bleeding After Kidney Biopsy in Patients with Rare Glomerulonephritis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Nocturnal Enuresis: The involuntary passage of urine during sleep past the age of expected bladder control (typically 5-7 years old). Also commonly known as bedwetting.
  • Monosymptomatic Nocturnal Enuresis: Bedwetting without any other lower urinary tract symptoms during the day.
  • Primary Monosymptomatic Nocturnal Enuresis (PMNE): Bedwetting in children who have never achieved a continuous dry period of more than 6 months.
  • Nocturia: The need to wake up one or more times during the night to urinate.
  • Nocturnal Polyuria: A condition where a person produces an abnormally large volume of urine during nighttime sleep, typically defined as more than 35% of the total 24-hour urine production occurring at night.
  • Benign Prostatic Hyperplasia (BPH): Non-cancerous enlargement of the prostate gland that can cause urinary symptoms including nocturia.
  • Desmopressin: A synthetic analog of the natural antidiuretic hormone vasopressin that reduces urine production by increasing water reabsorption in the kidneys.
  • DDAVP: An abbreviation for desmopressin acetate, the active pharmaceutical ingredient.
  • Antidiuretic Hormone (ADH): A hormone produced by the pituitary gland that helps the body retain water by reducing urine production.
  • Oral Lyophilisate: A medication formulation that is freeze-dried into a tablet that dissolves rapidly when placed under the tongue, also called a 'melt' formulation.
  • Hyponatremia: A condition characterized by abnormally low levels of sodium in the blood, which can occur as a side effect of desmopressin due to increased water retention.
  • Von Willebrand Factor: A blood protein that helps platelets stick to damaged blood vessel walls and is important in the blood clotting process.
  • Factor VIII: A clotting protein in the blood that, when deficient, causes hemophilia A.
  • Hemophilia A: A genetic bleeding disorder caused by a deficiency in clotting Factor VIII.
  • Von Willebrand Disease: A common inherited bleeding disorder caused by deficiency or dysfunction of von Willebrand factor.
  • Platelet Dysfunction: A condition where blood platelets don't function properly to form clots, which can increase bleeding risk.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including mechanisms of action and relationship between drug concentration and effect.
  • Initial Period of Undisturbed Sleep: The time elapsed from first falling asleep until either first void or morning arising, used as a measurement in nocturia studies.
  • Xerostomia: Abnormal dryness of the mouth due to reduced saliva production, sometimes reported as a side effect of certain medications.
  • Xerophthalmia: Abnormal dryness of the eye due to decreased tear production, sometimes reported as a side effect of certain medications.

References

  1. https://clinicaltrials.gov/study/NCT00477490
  2. https://clinicaltrials.gov/study/NCT06020456
  3. https://clinicaltrials.gov/study/NCT04545931
  4. https://clinicaltrials.gov/study/NCT02538302
  5. https://clinicaltrials.gov/study/NCT04420585
  6. https://clinicaltrials.gov/study/NCT00902057
  7. https://clinicaltrials.gov/study/NCT01694498
  8. https://clinicaltrials.gov/study/NCT05945420
  9. https://clinicaltrials.gov/study/NCT05628558
  10. https://clinicaltrials.gov/study/NCT00111215
  11. https://clinicaltrials.gov/study/NCT02368730
  12. https://clinicaltrials.gov/study/NCT02584231
  13. https://clinicaltrials.gov/study/NCT01606072
  14. https://clinicaltrials.gov/study/NCT00835211
  15. https://clinicaltrials.gov/study/NCT03051009
  16. https://clinicaltrials.gov/study/NCT01623206
  17. https://clinicaltrials.gov/study/NCT01439997
  18. https://clinicaltrials.gov/study/NCT06772584
  19. https://clinicaltrials.gov/study/NCT06285006
  20. https://clinicaltrials.gov/study/NCT00902265
  21. https://clinicaltrials.gov/study/NCT01435083